| AL 8697p38α inhibitor,potent and selective |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
AL 8697 Dilution Calculator
calculate
AL 8697 Molarity Calculator
calculate
| Cas No. | 1057394-06-5 | SDF | Download SDF |
| Chemical Name | 3-(3-(tert-butyl)-6,8-difluoro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-N-cyclopropyl-5-fluoro-4-methylbenzamide | ||
| Canonical SMILES | FC1=C(C)C(C2=C(F)C3=NN=C(C(C)(C)C)N3C=C2F)=CC(C(NC4CC4)=O)=C1 | ||
| Formula | C21H21F3N4O | M.Wt | 402.41 |
| Solubility | <40.24mg l="" in="" dmso;=""><20.12mg l="" in="" ethanol=""> | Storage | Store at -20°C |
| Physical Appearance | White solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
AL8697 is a selective p38 MAPK(mitogen-activated protein Kinase) inhibitor, which is also named P38 α inhibitor. It has the function of inhibiting the activity of P38 MAPK.[1]
Mitogen activated protein kinases (MAPK) are a group of signaling molecules that appear to play important roles in inflammatory processes. The P38 MAPK is one of the best described MAPK cascades. The p38 MAPK plays a key role in both the synthesis and the signalling of pro-inflammatory cytokines such as TNFa and IL-6 by monocyte/macrophages. The p38 MAPK are involved in the up-regulation of TNF production by murine macrophages.It has high activity in cardiovascular cells under a variety of cellular stresses. In cardiovascular disease, the P38 MAPK signaling pathways are activated.[2,3]
AL8697 function by the inhibition of P38 MAPK. It regulates a variety of cell activities related with P38 MAPK.
In a rat adjuvant-induced arthritis model, AL8697 exhibited a good anti-inflammatory effect and induced leukocytosis and increased total plasma cholesterol, these properties were evidently at 10 mg/kg. In addition, AL8697 partially restored the platelet count. The complex profile for AL8697 in rat AIA (adjuvant-induced arthritis) is not observed in human RA (rheumatoid arthritis).[1]
References: [1]. Balagué C, Pont M, Prats N, Godessart N. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study. Br J Pharmacol. 2012 Jun;166(4):1320-32 [2]. Ajizian SJ, English BK, Meals EA.Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma. J Infect Dis. 1999 Apr;179(4):939-44.[3]. Bao W, Behm DJ, Nerurkar SS, Ao Z, et al. Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol. 2007 Jun;49(6):362-8.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
探针的标记方式有放射性标记和非放射性标记。标记物质有放射性元素（如32P等）和非放射性物质（如生物素、地高辛等）。32P是最常用的核苷酸标记同位素，被标记的dNTP本身就带有磷酸基团，便于标记。特点是比活性高，可达9000Ci/mmol；发射的β射线能量高。用它标记的探针自显影时间短，灵敏度高。32P的半寿期短，虽使用不方便，但为废弃物的处理减轻了压力。非放射性标记法有酶标法和化学物标记法。酶标方法与免疫测定ELISA方法相似，只是被标记的核酸代替了被标记的抗体，事实上被标记的抗体也称为探针，现有许多商品是生物素、地高辛标记的。血凝素与生物素有非常高的亲和性，当血凝素标记上过氧化物酶或碱性磷酸酶，经杂交反应最终形成探针-生物素-血凝素酶复合物（ABC法），酶催化底物显色，观察结果。ABC法底物显色生成不溶物，以便观测结果。酶标记法复杂、重复性差，成本高，但便于运输、保存，灵敏度与放射物标记法相当。 ①缺口平移标记法。利用的是DNA聚合酶I能修复DNA链的功能。该法先由DNaseI在DNA双链上随机切出切口，然后DNA聚合酶I沿缺口水解5´端核苷酸，同时在3´端修复加入被标记核苷酸，切口平行推移。缺口平移法快速、简便、成本相对较低、比活性相对较高、标记均匀，多用于大分子DNA标记，(>1000bp最好)，但单链DNA、RNA不能用该法标记。
②随机引物法。随机引物是指含有各种可能排列顺序的寡聚核苷酸片断的混合物，因此它可以与任意核苷酸序列杂交，起到聚合酶反应的引物作用。将待标记的DNA探针片断变性后与随机引物一起杂交，然后以此杂交的寡聚核苷酸为引物，在大肠杆菌DNA聚合酶I大断段（KlenowFragment）催化下，合成与探针DNA互补的DNA链，当在反应体系中含有a-32P-dNTP时，即形成放射性同位素标记的DNA探针。具有上述优点，可代替缺口平移法。此外大小、单双DNA均可标记，标记均匀，标记率高，但也不能标记环状DNA。随机引物法标记探针一般长400~600bp。
③末端标记法（又叫尾标）。利用末端转移酶可进行“尾标”，尾标适用于寡核苷酸探针标记，寡核苷酸探针多用于核酸“点”突变的检测，该探针可用核酸合成仪人工合成，克隆出的探针一般较长，特异性好，标记量大，杂交的检出信号强。 1、4—6微米切片，用防脱片胶（多聚赖氨酸）处理过的玻片贴附
2、56—60℃烤片2—16h
3、新鲜二甲苯脱蜡，10minX2（趁热脱蜡）
4、100%乙醇5minX2次，不用浸水，直接空气干燥
5、加入50μl蛋白酶K工作液（蛋白酶K用蒸馏水稀释，浓度为25μg/ml），37℃消化10—15min
6、弃去蛋白酶K工作液，0.1MTBS洗涤3minX3次逐级酒精脱水（85%，95%，100%酒精）1minX3次然后空气干燥
7、加入20μl探针，加盖薄膜。（探针用预杂交液稀释，浓度为5μg/ml）。
8、95℃变性10—12min；立刻置于冰块上，防止复性。
9、37℃杂交16—20h
10、揭去薄膜，每张切片加入以下杂交后洗涤液：
>用2—3滴2XSSC37℃洗涤3minX2次；
>0.5XSSC37℃洗涤3minX2次；
>0.2XSSC37℃洗涤3minX2次；
11、0.1MPBS/TBS缓冲液洗涤，1minX3次
12、滴加小鼠抗地高辛生物素标记的抗体工作液，37℃孵育45—60min；
13、0.1MPBS浸洗，5minX3次
14、滴加高敏碱性磷酸酶链亲和素复合物工作液，37℃孵育45—60min。
15、0.1MPBS浸洗，5minX3次
16、滴加NBT/BCIP显色6—16h，
17、双蒸水终止反应（37℃10min—2h），双蒸水浸洗，5minX2次
18、滴加核固红，30秒—5min；
19、双蒸水浸洗，5minX3次
20、脱水、透明、封片
